Invariant Natural Killer T Cell
Invariant natural killer T cells (iNKT cells, or Type I NKT cells) are an innate-like T-lymphocyte subset expressing a conserved semi-invariant TCR (Vα24-Jα18 in humans; Vα14-Jα18 in mice) and the master transcription factor PLZF that recognizes glycolipid antigens presented by the MHC class I-like molecule CD1d.
Invariant natural killer T cells (iNKT cells, also designated Type I NKT cells) are an evolutionarily conserved lineage of innate-like αβ T lymphocytes that bridge innate pattern recognition and adaptive immunity by recognizing endogenous and microbial glycolipid antigens presented by the non-polymorphic, major histocompatibility complex (MHC) class I-like glycoprotein CD1d. Unlike conventional CD4+ and CD8+ T cells—which express hypervariable T-cell receptors (TCRs) specific for linear peptides bound to polymorphic MHC class I or II molecules and require days of clonal expansion before acquiring effector function—iNKT cells express a canonical, semi-invariant TCR alpha chain (Vα14–Jα18 in mice; Vα24–Jα18 paired with Vβ11 in humans) and are programmed during thymic development by the master transcription factor PLZF (ZBTB16, Promyelocytic Leukemia Zinc Finger) to exit the thymus in a pre-activated memory-like state (CD44highCD69+CD122+NK1.1+/−). Stationed within the vascular sinusoids of the liver, the splenic marginal zone, and the subcapsular sinus of lymph nodes, iNKT cells respond within 1 to 4 hours of glycolipid or cytokine stimulation by releasing rapid bursts of interferon-gamma (IFN-γ), interleukin-4 (IL-4), IL-17A, or granzyme B, trans-activating natural killer (NK) cells, licensing dendritic cells, and providing cognate help to lipid-presenting marginal zone B cells.
Semi-Invariant TCR Structure and CD1d Glycolipid Presentation
The Canonical Vα24-Jα18 / Vα14-Jα18 TCR and Parallel Docking Footprint
Generated via stochastic V(D)J recombination in CD4+CD8+ double-positive (DP) thymocytes, the Type I iNKT TCR displays remarkable inter-species conservation between rodents and primates:
- Murine iNKT TCR: Comprises an invariant TRAV11–TRAJ18 (Vα14–Jα18) alpha chain lacking N-nucleotide additions at the complementarity-determining region 3α (CDR3α) junction, paired preferentially with a restricted set of beta chains (TRBV13-2 / Vβ8.2, Vβ7, or Vβ2).
- Human iNKT TCR: Comprises the orthologous invariant TRAV10–TRAJ18 (Vα24–Jα18) alpha chain (sharing >80% amino acid identity with mouse CDR3α) paired predominantly with TRBV25-1 (Vβ11).
- Parallel CDR3α Docking Geometry: X-ray crystallographic structures resolved by Jamie Rossjohn, Dale I. Godfrey, and Ian A. Wilson demonstrated that whereas conventional peptide–MHC TCRs dock diagonally across both the α1/α2 helices of MHC and the central peptide using both CDR3α and CDR3β loops, the iNKT TCR docks in a tilted, parallel orientation over the distal F′-pocket end of the CD1d cleft. In this conserved footprint, the germline-encoded CDR1α and rearranged CDR3α loops make direct hydrogen-bond contacts with the hydrophilic polar carbohydrate headgroup of the glycolipid antigen protruding from CD1d, while the CDR2β loop stabilizes binding against the CD1d α1-helix.
Architecture of the Hydrophobic CD1d Antigen-Binding Groove
CD1d is a non-polymorphic transmembrane heavy chain non-covalently paired with β2-microglobulin (β2m). Instead of the shallow, electrostatically charged peptide-binding groove of classical MHC-I molecules, the α1 and α2 domains of CD1d fold into a deep, narrow, non-polar interior cavity (~1,400 Å3) divided into two hydrophobic channels—the A′ pocket (which accommodates an acyl chain up to 26 carbons long) and the F′ pocket (which binds a sphingosine or second fatty acyl chain up to 18 carbons long).
As intracellular CD1d recycles continuously from the plasma membrane through early and late endolysosomal compartments (guided by a tyrosine-based sorting motif YXXZ in its cytoplasmic tail that binds adaptor protein complexes AP-2 and AP-3), microsomal triglyceride transfer protein (MTP) in the endoplasmic reticulum and lysosomal lipid transfer proteins (saposins A, B, C, and D and GM2 activator protein) extract hydrophobic dual-chain lipids from membranes and load their alkyl tails into the A′ and F′ pockets of CD1d, leaving the polar sugar headgroup exposed at the solvent surface for TCR inspection:
- α-Galactosylceramide (α-GalCer / KRN7000): Originally isolated in 1993 from the marine sponge Agelas mauritianus (derived from symbiotic marine bacteria and later shown by Dennis L. Kasper to be synthesized in the mammalian gut by the human commensal Bacteroides fragilis), α-GalCer features a galactose ring linked in an α-anomeric configuration to a phytosphingosine C18 base and a C26 hexacosanoyl fatty acid chain, serving as the prototypical nanomolar-potency pan-iNKT agonist discovered by Masaru Taniguchi and colleagues (1997).
- Microbial Glycolipids: Pathogenic and commensal bacteria lacking lipopolysaccharide or expressing specialized cell-wall glycolipids—including α-glucuronosylceramides and α-galacturonosylceramides from Sphingomonas and Novosphingobium species, α-galactosyldiacylglycerols from the Lyme disease spirochete Borrelia burgdorferi, and α-glucosyldiacylglycerols from Streptococcus pneumoniae—directly activate the iNKT TCR via CD1d.
- Cytokine-Driven Indirect Activation (IL-12 + IL-18 + Self-Lipids): During infections with LPS-positive Gram-negative bacteria (Salmonella, Escherichia coli) or viruses that lack α-linked glycolipids, Toll-like receptor (TLR) signaling on dendritic cells and macrophages induces IL-12 and IL-18 alongside upregulation of endogenous β-linked or trace α-linked mammalian self-glycolipids (such as isoglobotrihexosylceramide, β-glucosylceramide, and plasmalogen lysophosphatidylethanolamine), triggering robust IFN-γ secretion from iNKT cells even under weak TCR stimulation.
| Parameter / Subset | NKT1 Subset (TH1-like) | NKT2 Subset (TH2-like) | NKT17 Subset (TH17-like) | Type II (Diverse) NKT Cell |
|---|---|---|---|---|
| TCR Repertoire | Semi-invariant Vα14-Jα18 (mouse) / Vα24-Jα18 + Vβ11 (human) | Semi-invariant Vα14-Jα18 / Vα24-Jα18 + Vβ11 | Semi-invariant Vα14-Jα18 / Vα24-Jα18 + Vβ11 | Oligoclonal / polyclonal TCRs (Vα3.2-Jα9, Vα8); α-GalCer non-reactive |
| Transcription Factor Profile | PLZFlow, T-bethigh, Eomes+/− | PLZFhigh, GATA3high, IRF4+ | PLZFint, RORγthigh (Rorc), c-Maf+ | PLZFlow/int, variable T-bet / GATA3 |
| Surface Phenotype & Cytokines | NK1.1+ (CD161+), CXCR3+, CD122high; secretes IFN-γ, minor IL-4, Granzyme B | NK1.1−, CD4+, ICOShigh, IL-17RB+ (IL-25R); secretes IL-4, IL-13 | NK1.1−, CD4−, CCR6+, CD103+,Syndecan-1 (CD138)+; secretes IL-17A, IL-22 | Recognizes sulfatide, lysophospholipids, and β-GlcCer on CD1d; often immunoregulatory |
| Primary Anatomical Residency | Liver sinusoids (20–30% of mouse hepatic lymphocytes; 1–2% in humans) & splenic red pulp | Mesenteric lymph nodes, thymic medulla, and lung lamina propria | Peripheral lymph nodes (subcapsular sinus), skin dermis, and lung mucosa | Abundant in human liver, bone marrow, and intestinal mucosa (outnumbering Type I in humans) |
Homotypic Thymic Selection, SLAM–SAP, and PLZF Sublineage Polarization
Unlike conventional thymocytes—which are positively selected on cortical thymic epithelial cells (cTECs) presenting self-peptides on MHC-I or MHC-II—iNKT precursors undergo homotypic positive selection on other CD4+CD8+ double-positive (DP) cortical thymocytes expressing CD1d loaded with endogenous self-glycolipids. Because DP thymocytes lack classical CD80/CD86 costimulators, iNKT selection requires homotypic engagement of SLAM family receptors (SLAM / CD150 and Ly108 / SLAMF6) coupled to the cytoplasmic adaptor SAP (SH2D1A) and the Src-family tyrosine kinase Fyn. Consequently, humans with X-linked lymphoproliferative disease type 1 (XLP1, SH2D1A deficiency) completely lack iNKT cells alongside defective follicular helper T cell germinal center responses.
Strong agonistic TCR + SLAM–SAP–Fyn signaling in stage 0 (CD24highCD44lowNK1.1−) iNKT thymocytes induces high levels of the transcription factor Egr2 (Early Growth Response 2), which binds directly to the promoter of Zbtb16 (encoding PLZF). PLZF—first identified as the master regulator of iNKT effector poise by Albert Bendelac and Derek B. Sant'Angelo (2008) and shared with mucosal-associated invariant T cells and innate lymphoid cell progenitors—drives intrathymic proliferation, downregulates CD24, induces memory/homing receptors (CD44, CXCR3, CXCR6,CCR6, LFA-1), and maintains preformed cytoplasmic mRNA transcripts for Ifng and Il4 so mature iNKT cells can secrete cytokines within 60 minutes of peripheral activation. Within the thymus, developing iNKT cells bifurcate into three stable functional sublineages—NKT1 (PLZFlowT-bethigh), NKT2 (PLZFhighGATA3high), and NKT17 (PLZFintRORγthigh)—alongside specialized follicular helper NKT cells (NKTFH, Bcl-6+CXCR5+PD-1+) and adipose-resident regulatory NKT10 cells (PLZF−E4BP4+IL-10+) that maintain metabolic homeostasis in visceral white adipose tissue. Before emigrating, thymic NKT2 cells constitutively secrete steady-state IL-4, which acts in paracrine fashion on bystander CD8+ single-positive thymocytes to induce Eomesodermin and generate virtual memory T cells.
Vascular Patrol, CD40L Dendritic Cell Licensing, and CAR-iNKT Therapy
Intravascular Hepatic Patrol and Subcapsular Sinus Surveillance
In peripheral tissues, iNKT cells occupy strategic anatomical bottlenecks where blood- or lymph-borne pathogens first enter lymphoid organs:
- Hepatic Sinusoidal Crawling: Within the liver, CXCR6+LFA-1high NKT1 cells patrol continuously along the luminal surface of CXCL16+ICAM-1+ liver sinusoidal endothelial cells (LSECs) and Kupffer cells, crawling randomly in the direction of and against sinusoidal blood flow at 10–20 μm/min. When Kupffer cells phagocytose blood-borne Borrelia burgdorferi or Streptococcus pneumoniae and display microbial glycolipids on CD1d, patrolling iNKT cells arrest rapidly via LFA-1 conformational activation and release IFN-γ to clear bacteremia.
- Lymph Node Subcapsular Sinus and Splenic Marginal Zone: In lymph nodes, iNKT cells reside directly beneath subcapsular sinus macrophages (CD169+ SCS macrophages), which capture lymph-borne lipid antigens and rapidly activate iNKT cells within 2 hours of immunization. In the spleen, CD1dhigh marginal zone B cells internalize glycolipid–protein conjugates via their B-cell receptor and present the lipid on CD1d to NKTFH cells, receiving cognate CD40L and IL-21 help to drive rapid extrafollicular IgM and IgG antibody production.
Trans-Activation of NK/CD8+ Cells and Allogeneic CAR-iNKT Immunotherapy
Upon recognizing α-GalCer on a CD8α+/CD103+ conventional dendritic cell (cDC1), the activated iNKT cell upregulates CD40 Ligand (CD40L / CD154) and secretes IFN-γ and CCL17. CD40L ligates CD40 on the dendritic cell, "licensing" the DC to upregulate CD70, CD80, CD86, and secrete bioactive IL-12p70 and IL-15. This DC–iNKT dialog triggers a secondary trans-activation cascade: within 6 to 12 hours, NK cells amplify systemic IFN-γ and perforin/granzyme cytotoxicity against NK-sensitive metastases, while CCL17 attracts CCR4+ naive CD8+ T cells to the licensed cDC1 to enhance peptide cross-presentation and CD8+ memory differentiation.
In clinical oncology, because the iNKT TCR recognizes non-polymorphic CD1d rather than polymorphic HLA class I or II molecules, allogeneic donor-derived iNKT cells do not cause graft-versus-host disease (GvHD)—and in fact suppress GvHD via NKT2/NKT10 IL-4 and IL-10 production while killing CD1d+ tumor cells and immunosuppressive tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells. Consequently, off-the-shelf allogeneic CAR-iNKT cells (such as GD2-specific CAR-iNKT cells co-expressing IL-15 for neuroblastoma and CD19-CAR-iNKT cells for B-cell lymphomas) combine CAR-directed tumor lysis with endogenous TCR-mediated depletion of CD1d+ myeloid-derived suppressor cells in the tumor microenvironment.
Frequently Asked Questions
How does CD1d present glycolipid antigens instead of peptides?
Unlike classical MHC class I and II molecules—which possess shallow, polar grooves with hydrogen-bonding networks tailored to bind the peptide backbone of 8- to 25-amino-acid protein fragments—CD1d folds into a deep, narrow, non-polar cavity lined by hydrophobic amino acids and divided into two lipid-binding channels (A′ and F′ pockets). Lysosomal lipid-transfer proteins (saposins) insert the hydrophobic fatty acyl and sphingosine chains of glycolipids deep into the A′ and F′ pockets of CD1d, positioning the hydrophilic polar carbohydrate (sugar) headgroup at the outer entrance of the groove where it is recognized directly by the CDR1α and CDR3α loops of the semi-invariant iNKT TCR.
Why is the transcription factor PLZF required for iNKT cell function?
PLZF (ZBTB16) is induced in developing iNKT thymocytes by strong agonistic TCR and SLAM–SAP–Fyn signaling during homotypic selection on CD1d+ double-positive thymocytes. Without PLZF, iNKT cells arrest as naive-like CD44lowCD62Lhigh lymphocytes that recirculate through lymph node paracortices and require days of proliferation before producing cytokines. PLZF epigenetically opens the chromatin of effector cytokine loci (Ifng, Il4, Il17a), upregulates tissue-homing chemokine receptors (CXCR6, CXCR3, CCR6) and integrins (LFA-1), and enables iNKT cells to reside in liver sinusoids and splenic marginal zones poised for immediate cytokine release within hours of stimulation.
Why can allogeneic CAR-iNKT cells be administered across HLA-mismatched patients without causing graft-versus-host disease?
Conventional αβ T cells express diverse TCRs that recognize polymorphic donor-vs.-recipient HLA class I and II proteins, causing acute graft-versus-host disease (GvHD) unless the endogenous TCR is genetically knocked out. In contrast, every iNKT cell expresses the monomorphic Vα24-Jα18 / Vβ11 TCR restricted to CD1d—a monomorphic protein whose amino acid sequence is identical across all humans. Because the iNKT TCR does not recognize mismatched MHC class I or II molecules, third-party donor CAR-iNKT cells can be infused as off-the-shelf allogeneic immunotherapies without eliciting GvHD.
References
- Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., Koseki, H., & Taniguchi, M. (1997). "CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides." Science, 278(5343), 1626–1629. https://doi.org/10.1126/science.278.5343.1626
- Borg, N. A., Wun, K. S., Kjer-Nielsen, L., Wilce, M. C. J., Pellicci, D. G., Koh, R., Besra, G. S., Bharadwaj, M., Godfrey, D. I., McCluskey, J., & Rossjohn, J. (2007). "CD1d–lipid-antigen recognition by the semi-invariant NKT T-cell receptor." Nature, 448(7149), 44–49. https://doi.org/10.1038/nature05907
- Savage, A. K., Constantinides, M. G., Han, J., Picard, D., Martin, E., Li, B., Lantz, O., & Bendelac, A. (2008). "The transcription factor PLZF directs the effector program of the NKT cell lineage." Immunity, 29(3), 391–403. https://doi.org/10.1016/j.immuni.2008.07.011
- Crosby, C. M., & Kronenberg, M. (2018). "Tissue-specific functions of invariant natural killer T cells." Nature Reviews Immunology, 18(9), 559–574. https://doi.org/10.1038/s41577-018-0034-2